Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

E-Therapeutics stock

ETX.L
GB00B2823H99
A0M8VQ

Price

0.09
Today +/-
+0
Today %
+0 %
P

E-Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the E-Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the E-Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the E-Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze E-Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

E-Therapeutics Stock Price History

DateE-Therapeutics Price
5/8/20240.09 undefined
5/7/20240.10 undefined

E-Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into E-Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by E-Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects E-Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of E-Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into E-Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing E-Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on E-Therapeutics’s growth potential.

E-Therapeutics Revenue, EBIT and net profit per share

DateE-Therapeutics RevenueE-Therapeutics EBITE-Therapeutics Net Income
2024e515,000 undefined0 undefined-9.27 M undefined
2023475,000 undefined-10.24 M undefined-8.27 M undefined
2022477,000 undefined-9.57 M undefined-8.07 M undefined
2021317,000 undefined-4.49 M undefined-3.68 M undefined
2020456,000 undefined-2.89 M undefined-2.35 M undefined
201944,000 undefined-5.11 M undefined-4 M undefined
20180 undefined-6.77 M undefined-5.36 M undefined
20170 undefined-13.53 M undefined-13.13 M undefined
20160 undefined-11.56 M undefined-8.82 M undefined
20150 undefined-10.18 M undefined-7.78 M undefined
20140 undefined-6.72 M undefined-5.04 M undefined
20130 undefined-5.25 M undefined-4.18 M undefined
20120 undefined-4.03 M undefined-3.24 M undefined
20110 undefined-2.48 M undefined-2.31 M undefined
20100 undefined-2.16 M undefined-1.78 M undefined
200970,000 undefined-2.02 M undefined-1.55 M undefined
200860,000 undefined-1.81 M undefined-1.97 M undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined
20050 undefined0 undefined0 undefined

E-Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20052006200720082009201020112012201320142015201620172018201920202021202220232024e
00000000000000000000
--------------------
--------------------
00000000000000000000
000-1-1-1-2-3-4-5-7-8-13-5-3-2-3-8-8-9
------100.0050.0033.3325.0040.0014.2962.50-61.54-40.00-33.3350.00166.67-12.50
55.7155.7155.7151.5455.7160.1165.84131.01138.16254.4264.15264.42267.06268.46268.58268.86373.22488.34537.350
--------------------
Details

Keystats

ⓘ

Revenue and Growth

The E-Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the E-Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (k)PROVISIONS (M)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2005200620072008200920102011201220132014201520162017201820192020202120222023
                                     
0001.980.412.880.9313.919.7843.15024.8413.989.65.93.8413.0326.431.69
00.871.9600000000000.0900.02000
0000.520000000001.3600.570.831.711.76
0000000000000000000
0001008030701802005900918501504328149296501553
00.871.962.60.492.91114.099.9843.74025.7614.4811.566.234.5814.1528.6134
02030604030201401501200645171429380805400
0000000000000000000
00000000000000000236259
0405070150260270340380500074015613511911082102239
0000000000000000000
0000000000000000000
00.060.080.130.190.290.290.480.530.6200.80.210.210.160.20.161.140.9
00.932.042.730.683.21.2914.5710.5144.36026.5614.6811.766.394.7914.3129.7534.9
                                     
000606070701401402600264268269269269421515582
00.942.044.684.687.577.6525.5525.5764.48064.5765.1465.1565.1765.1877.6799.24112.61
000-2.25-3.79-5.15-7.45-10.97-15.13-20.130-36.41-49.43-54.69-58.63-60.94-64.21-72.03-80.15
0000000000000000000
0000000000000000000
00.942.042.490.952.490.2714.7210.5844.61028.4315.9810.746.84.513.8827.7333.04
0002302902003505508901,0005325628896371355550199429
0000000000001.050.370.350.140.230.860.8
000000000000813225241204070
0000000000000000000
0000000000000004623391295
0000.230.290.20.350.550.8910.530.561.951.020.710.260.431.491.6
000001.031.04000000000.0200.30
0000000000000000000
0000000000000000000
000001.031.04000000000.0200.30
0000.230.291.231.390.550.8910.530.561.951.020.710.280.431.791.6
00.942.042.721.243.721.6615.2711.4745.610.5328.9917.9311.767.514.7914.3129.5234.64
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of E-Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand E-Therapeutics's financial health and stability.

Assets

E-Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that E-Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of E-Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into E-Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (k)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20072008200920102011201220132014201520162017201820192020202120222023
-1-1-1-1-2-3-4-5-7-8-13-5-3-2-3-8-8
00000000002000000
00000000000000000
00000000023210011
000000-1-1-2-2-3-1-100-1-1
00000000000000000
00000000-1-2-2-2-1-100-1
-1-2-1-1-1-3-4-5-9-9-9-4-3-2-3-7-8
00000000000000000
00000-72-304137720-5-915
00000-72-304137720-4-815
00000000000000000
0001,0000-1,00000000000000
1403017039000000122113
1404016039000000122213
-----------------
00000000000000000
01-12-15-12-54-12-1-24420
-1.1-2.42-1.63-1.78-2.05-3.51-4.41-5.89-10.04-9.32-9.6-4.48-3.73-2.04-3.43-8.76-8.22
00000000000000000

E-Therapeutics stock margins

The E-Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of E-Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for E-Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the E-Therapeutics's sales revenue. A higher gross margin percentage indicates that the E-Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the E-Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the E-Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the E-Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the E-Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the E-Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

E-Therapeutics Margin History

E-Therapeutics Gross marginE-Therapeutics Profit marginE-Therapeutics EBIT marginE-Therapeutics Profit margin
2024e100 %0 %-1,799.75 %
2023100 %-2,155.58 %-1,741.89 %
2022100 %-2,006.29 %-1,691.82 %
2021100 %-1,414.83 %-1,162.15 %
2020100 %-633.33 %-514.69 %
2019100 %-11,622.73 %-9,088.64 %
2018100 %0 %0 %
2017100 %0 %0 %
2016100 %0 %0 %
2015100 %0 %0 %
2014100 %0 %0 %
2013100 %0 %0 %
2012100 %0 %0 %
2011100 %0 %0 %
2010100 %0 %0 %
200985.71 %-2,885.71 %-2,214.29 %
200866.67 %-3,016.67 %-3,283.33 %
2007100 %0 %0 %
2006100 %0 %0 %
2005100 %0 %0 %

E-Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The E-Therapeutics earnings per share therefore indicates how much revenue E-Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue E-Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates E-Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of E-Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating E-Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

E-Therapeutics Revenue, EBIT and net profit per share

DateE-Therapeutics Sales per ShareE-Therapeutics EBIT per shareE-Therapeutics Earnings per Share
2024e0 undefined0 undefined-0.02 undefined
20230 undefined-0.02 undefined-0.02 undefined
20220 undefined-0.02 undefined-0.02 undefined
20210 undefined-0.01 undefined-0.01 undefined
20200 undefined-0.01 undefined-0.01 undefined
20190 undefined-0.02 undefined-0.01 undefined
20180 undefined-0.03 undefined-0.02 undefined
20170 undefined-0.05 undefined-0.05 undefined
20160 undefined-0.04 undefined-0.03 undefined
20150 undefined-0.04 undefined-0.03 undefined
20140 undefined-0.03 undefined-0.02 undefined
20130 undefined-0.04 undefined-0.03 undefined
20120 undefined-0.03 undefined-0.02 undefined
20110 undefined-0.04 undefined-0.04 undefined
20100 undefined-0.04 undefined-0.03 undefined
20090 undefined-0.04 undefined-0.03 undefined
20080 undefined-0.04 undefined-0.04 undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined
20050 undefined0 undefined0 undefined

E-Therapeutics business model

E-Therapeutics PLC is an English biotechnology company that develops medical compounds using innovative technologies. It was founded in 2003 by Prof. Malcolm Young and has made significant progress in the field of drug development since then. The company has always aimed for an innovative business model focused on identifying new compounds through computer simulations. E-Therapeutics has developed a unique platform called Network Pharmacology, which simulates complex biological systems and identifies potential drug candidates. The platform uses mathematical models and artificial intelligence to identify molecules that can have a positive effect on specific cells. E-Therapeutics' business model is designed to collaborate with partners in developing new drug candidates. The company offers its platform and expertise to support customers in identifying new chemical compounds. E-Therapeutics works closely with top pharmaceutical companies to advance the development of new drugs. E-Therapeutics is divided into three divisions, each focusing on different areas of medical drug research: 1. Oncology division: This division focuses on developing drugs for the treatment of cancer. E-Therapeutics uses its unique platform to develop targeted therapies tailored to the individual needs of the patient. The platform can also be used to identify new biomarkers and potential therapeutics for a variety of cancer diseases. 2. Neurology division: E-Therapeutics' neurology division focuses on identifying drugs for the treatment of neurological diseases such as Alzheimer's, Parkinson's, and Huntington's. E-Therapeutics' platform has already been used to identify new drug candidates that could have a positive effect on the symptoms of these diseases. 3. Infectious Diseases division: E-Therapeutics' infectious diseases division focuses on the development of drugs for the treatment of infectious diseases such as HIV and influenza. E-Therapeutics uses its platform to identify new compounds that have the potential to fight infections and prevent the spread of diseases. E-Therapeutics has a pipeline of products targeting different medical fields. One promising product is ETS-101, a novel drug candidate for the treatment of pain. ETS-101 has already shown positive results in preclinical studies and is currently in phase 1 studies. Another promising product is ETS-6103, being developed for the treatment of depression. ETS-6103 has been successfully tested in preclinical studies and is currently in phase 2 clinical development. In summary, E-Therapeutics focuses on developing drugs that work at a biological level. The company's innovative business model, unique platform, and collaboration with top pharmaceutical companies make it a key player in medical drug research. With a pipeline of promising products, E-Therapeutics has the potential to change the face of medical drug research and advance the world of medicine. Answer: E-Therapeutics PLC is an English biotechnology company that develops medical compounds using innovative technologies. It focuses on identifying new compounds through computer simulations and has developed a unique platform called Network Pharmacology. The company collaborates with partners to develop new drug candidates and is divided into divisions focused on oncology, neurology, and infectious diseases. E-Therapeutics has a pipeline of promising products, including ETS-101 for pain treatment and ETS-6103 for depression treatment. It aims to advance medical drug research and contribute to the field of medicine. E-Therapeutics is one of the most popular companies on Eulerpool.com.

E-Therapeutics SWOT Analysis

Strengths

E-Therapeutics PLC possesses several key strengths that contribute to their success. These strengths include:

  • Advanced Technology: E-Therapeutics PLC utilizes state-of-the-art technology in their drug discovery and development processes, giving them a competitive advantage in the industry.
  • Strong Intellectual Property (IP): The company holds a strong portfolio of intellectual property rights, including patents and proprietary algorithms, which protect their innovative solutions and provide them with long-term value.
  • Experienced Management Team: E-Therapeutics PLC is led by a highly skilled and experienced management team with a deep understanding of the pharmaceutical industry. Their expertise enables effective decision-making and strategic direction.
  • Collaborative Partnerships: The company has established strategic partnerships with leading pharmaceutical companies and research institutions, facilitating knowledge sharing, resources pooling, and potential revenue generation.

Weaknesses

Despite their strengths, E-Therapeutics PLC also faces certain weaknesses that require attention and mitigation:

  • Dependency on Research Funding: E-Therapeutics PLC relies heavily on external funding for their research and development activities. Any fluctuations or reduction in funding availability may hinder their progress and limit their ability to pursue new opportunities.
  • Limited Product Portfolio: The company currently has a relatively limited product portfolio, which increases their reliance on the success of individual drug candidates. This lack of diversification poses a risk to their revenue stream and overall stability.
  • Regulatory Challenges: E-Therapeutics PLC operates in a highly regulated industry, and compliance with various regulatory requirements can be time-consuming and costly. Failure to meet these obligations may result in penalties, delays, or setbacks in their development processes.

Opportunities

E-Therapeutics PLC has several opportunities to pursue for growth and further success:

  • Increasing Demand for Drug Discovery Solutions: The global demand for effective drug discovery solutions is on the rise, presenting a significant market opportunity for E-Therapeutics PLC to expand their customer base and revenue potential.
  • Emerging Markets: The company can tap into emerging markets, such as Asia and Latin America, where there is a growing need for innovative pharmaceutical solutions. Establishing partnerships or expanding operations in these regions can lead to substantial growth.
  • Advancements in Personalized Medicine: With the increasing focus on personalized medicine, E-Therapeutics PLC can capitalize on this trend by leveraging their advanced technology and expertise to develop tailored therapeutic solutions for specific patient populations.

Threats

E-Therapeutics PLC should be aware of potential threats that could impact their business and take appropriate measures to mitigate them:

  • Intense Competition: The pharmaceutical industry is highly competitive, with numerous established companies and new entrants vying for market share. E-Therapeutics PLC needs to continually innovate and differentiate themselves to stay ahead.
  • Stringent Regulatory Environment: The regulatory landscape for drug development and commercialization is stringent and subject to constant changes. Compliance with evolving regulations may increase costs and lengthen time to market, posing a challenge for E-Therapeutics PLC.
  • Intellectual Property Infringement: The risk of intellectual property infringement is present in the pharmaceutical industry. E-Therapeutics PLC must protect their IP rights and be prepared to take legal action to defend against potential infringements that could harm their competitive advantage.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

E-Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

E-Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

E-Therapeutics shares outstanding

The number of shares was E-Therapeutics in 2023 — This indicates how many shares 537.346 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue E-Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates E-Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of E-Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating E-Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for E-Therapeutics.

E-Therapeutics shareholders

%
Name
Stocks
Change
Date
29.18028 % Griffiths (Richard Ian)170,510,90506/2/2023
17.43432 % M&G Investment Management Ltd.101,875,00006/2/2023
8.89899 % Quested (Robert)52,000,00006/2/2023
8.71787 % Mortazavi (Ali)50,941,66606/2/2023
5.09456 % Trillian, Ltd.29,769,32606/2/2023
4.87384 % Bank J. Safra Sarasin AG (Asset Management)28,479,594-1,992,6177/25/2023
4.58851 % Richardson (D H)26,812,31206/2/2023
2.44112 % Schroder Investment Management Ltd. (SIM)14,264,364012/31/2023
1.15413 % Newcastle University Holdings Ltd6,744,000010/15/2023
1.05533 % Fidelity Management & Research Company LLC6,166,66608/22/2023
1
2
3
4

E-Therapeutics Executives and Management Board

Mr. Ali Mortazavi(52)
E-Therapeutics Chief Executive Officer, Executive Director (since 2020)
Compensation 270,000
Mr. Michael Bretherton
E-Therapeutics Interim Chief Financial Officer, Non-Executive Director (since 2020)
Compensation 120,000
Prof. Trevor Jones(79)
E-Therapeutics Independent Non-Executive Chairman of the Board
Compensation 55,000
Mr. Timothy Bretherton
E-Therapeutics Director of Finance and Operations
Ms. Laura Roca-alonso
E-Therapeutics Chief Operating Officer
1
2

E-Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Galapagos Stock
Galapagos
SupplierCustomer0,050,470,27-0,83-0,62-0,73
WuXi AppTec Co H Stock
WuXi AppTec Co H
SupplierCustomer-0,190,51-0,080,66-0,030,47
Novo Nordisk B Stock
Novo Nordisk B
SupplierCustomer-0,450,34-0,43-0,500,250,74
1

Most common questions regarding E-Therapeutics

What values and corporate philosophy does E-Therapeutics represent?

E-Therapeutics PLC represents values of innovation, scientific excellence, and collaboration in the field of therapeutics. The company's corporate philosophy revolves around utilizing network pharmacology and computational biology to discover and develop novel drugs. E-Therapeutics PLC is committed to leveraging advanced technology and big data to identify new therapeutic targets and accelerate the drug discovery process. With a focus on precision medicine, the company aims to address unmet medical needs and improve patient outcomes. E-Therapeutics PLC's dedication to scientific rigor and strategic partnerships allows it to remain at the forefront of innovative drug development.

In which countries and regions is E-Therapeutics primarily present?

E-Therapeutics PLC is primarily present in the United Kingdom.

What significant milestones has the company E-Therapeutics achieved?

E-Therapeutics PLC has achieved significant milestones in their journey. This dynamic company has successfully developed innovative therapies that have garnered attention in the healthcare industry. E-Therapeutics PLC has consistently showcased their commitment to research and development, resulting in groundbreaking pharmaceutical advancements. Their pioneering work has led to notable achievements such as the successful completion of clinical trials, regulatory approvals for their therapies, and strategic collaborations with renowned organizations. E-Therapeutics PLC's remarkable progress has solidified their position as a leading player in the market, revolutionizing the field of therapeutics and positively impacting the lives of patients worldwide.

What is the history and background of the company E-Therapeutics?

E-Therapeutics PLC is a leading biotechnology company based in the United Kingdom. Founded in 2003, the company focuses on the discovery and development of novel drugs using its proprietary network-driven drug discovery (NDD) platform. E-Therapeutics PLC combines approaches from network pharmacology, computational biology, and artificial intelligence to identify promising drug candidates. With a team of expert scientists and partnerships with leading academic institutions, E-Therapeutics PLC has made significant advancements in various therapeutic areas, including oncology and neuroscience. The company's innovative approach and dedication to scientific excellence have positioned it as a key player in the biotech industry.

Who are the main competitors of E-Therapeutics in the market?

The main competitors of E-Therapeutics PLC in the market include pharmaceutical companies such as GlaxoSmithKline, AstraZeneca, and Johnson & Johnson. These industry giants have a strong presence and compete with E-Therapeutics in various therapeutic areas, including drug discovery and development. Additionally, other smaller biotechnology companies focusing on similar research and product pipelines also pose competition to E-Therapeutics.

In which industries is E-Therapeutics primarily active?

E-Therapeutics PLC is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of E-Therapeutics?

The business model of E-Therapeutics PLC focuses on utilizing network pharmacology and computational methods to identify novel drug candidates for a range of diseases. By leveraging its proprietary drug discovery platform, E-Therapeutics aims to accelerate the development of more effective and targeted therapies. The company collaborates with pharmaceutical partners and academic institutions to advance its drug discovery programs. E-Therapeutics utilizes a data-driven approach, analyzing vast amounts of biological and chemical data to identify potential drug targets and optimize treatment options. This enables E-Therapeutics PLC to provide innovative solutions in the field of drug discovery.

What is the P/E ratio of E-Therapeutics 2024?

The E-Therapeutics P/E ratio is -5.22.

What is the P/S ratio of E-Therapeutics 2024?

The E-Therapeutics P/S ratio is 93.91.

What is the Quality Investing of E-Therapeutics?

The Quality Investing for E-Therapeutics is 4/10.

What is the revenue of E-Therapeutics 2024?

The expected E-Therapeutics revenue is 515,000 GBP.

How high is the profit of E-Therapeutics 2024?

The expected E-Therapeutics profit is -9.27 M GBP.

What is the business model of E-Therapeutics

E-Therapeutics PLC is an innovative biotech company based in the UK. The company's business model is based on the discovery and development of novel drugs for the treatment of serious diseases such as cancer, inflammation, and neurological disorders. E-Therapeutics uses a unique computer-based platform that allows for the simulation and analysis of complex biological systems and disease processes. The key focus of E-Therapeutics is the discovery of new drugs. The company utilizes its innovative network pharmacology platform to analyze the complex relationship between genetic factors, signaling pathways, and drug effects. Based on this analysis, E-Therapeutics systematically develops new drugs that specifically target certain signaling pathways and thus influence underlying disease processes. Another important aspect of E-Therapeutics is the clinical development of new drugs. The company works closely with clinical partners and contract research organizations to test its drugs in clinical trials and demonstrate their efficacy and safety. E-Therapeutics employs a strategic pipeline planning approach to ensure that the most promising drugs are quickly and efficiently advanced into clinical development. In addition to drug discovery and development, E-Therapeutics also offers consulting and services in the field of network pharmacology. The company supports industry and academic research partners in the analysis and interpretation of complex data, as well as the identification of new target structures and drug candidates. One example of a product from E-Therapeutics' pipeline is the drug ETX-155, which is being developed for the treatment of cancer. ETX-155 specifically targets the p38 signaling pathway, which plays an important role in many types of cancer. In preclinical studies, ETX-155 has already shown promising results and is currently in Phase I clinical development. Overall, E-Therapeutics' business model provides a promising basis for the development of new, effective drugs based on the latest technologies and analytical methods. The company relies on collaborative partnerships with clinical partners and contract research organizations to quickly and efficiently bring its drugs to market and make a significant contribution to improving healthcare. The answer is E-Therapeutics PLC is an innovative biotech company based in the UK that focuses on the discovery and development of novel drugs for the treatment of serious diseases such as cancer, inflammation, and neurological disorders. The company utilizes a computer-based platform to simulate and analyze complex biological systems and disease processes. E-Therapeutics also offers consulting and services in network pharmacology. They have a drug in their pipeline, ETX-155, being developed for cancer treatment, which targets the p38 signaling pathway. The company works closely with clinical partners and contract research organizations to test and develop their drugs efficiently.

What is the E-Therapeutics dividend?

E-Therapeutics pays a dividend of 0 GBP distributed over payouts per year.

How often does E-Therapeutics pay dividends?

The dividend cannot currently be calculated for E-Therapeutics or the company does not pay out a dividend.

What is the E-Therapeutics ISIN?

The ISIN of E-Therapeutics is GB00B2823H99.

What is the E-Therapeutics WKN?

The WKN of E-Therapeutics is A0M8VQ.

What is the E-Therapeutics ticker?

The ticker of E-Therapeutics is ETX.L.

How much dividend does E-Therapeutics pay?

Over the past 12 months, E-Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, E-Therapeutics is expected to pay a dividend of 0 GBP.

What is the dividend yield of E-Therapeutics?

The current dividend yield of E-Therapeutics is .

When does E-Therapeutics pay dividends?

E-Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of E-Therapeutics?

E-Therapeutics paid dividends every year for the past 0 years.

What is the dividend of E-Therapeutics?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is E-Therapeutics located?

E-Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von E-Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of E-Therapeutics from 11/19/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 11/19/2024.

When did E-Therapeutics pay the last dividend?

The last dividend was paid out on 11/19/2024.

What was the dividend of E-Therapeutics in the year 2023?

In the year 2023, E-Therapeutics distributed 0 GBP as dividends.

In which currency does E-Therapeutics pay out the dividend?

The dividends of E-Therapeutics are distributed in GBP.

All fundamentals about E-Therapeutics

Our stock analysis for E-Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of E-Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.